MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT04763681 | COMPLETED | NA
54 participants

Couple HOPES and COVID-19

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-01-01
Completion:
2024-01-31
Conditions
  • Posttraumatic Stress Disorder
Interventions
  • BEHAVIORAL
No Results Yet
NCT04616534 | ACTIVE_NOT_RECRUITING | PHASE1
14 participants

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-06-01
Completion:
2025-04-01
Conditions
  • Advanced Fallopian Tube Carcinoma
  • Advanced Malignant Solid Neoplasm
  • Advanced Ovarian Carcinoma
  • Advanced Pancreatic Adenocarcinoma
  • Advanced Primary Peritoneal Carcinoma
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Fallopian Tube Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage III Primary Peritoneal Cancer AJCC v8
  • Stage IV Fallopian Tube Cancer AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Stage IV Primary Peritoneal Cancer AJCC v8
  • Unresectable Pancreatic Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
Results Available
NCT04595747 | ACTIVE_NOT_RECRUITING | PHASE2
48 participants

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-05-03
Completion:
2027-07-31
Conditions
  • Locally Advanced Gastrointestinal Stromal Tumor
  • Locally Advanced Sarcoma
  • Metastatic Gastrointestinal Stromal Tumor
  • Metastatic Sarcoma
  • Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
  • Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
  • Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
  • Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04554914 | ACTIVE_NOT_RECRUITING | PHASE2
190 participants

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-07-14
Completion:
2027-06-30
Conditions
  • Epstein-Barr Virus (EBV)-Associated Diseases
  • EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
  • EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
  • EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
  • EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
  • Solid Organ Transplant Complications
  • Lymphoproliferative Disorders
  • Allogeneic Hematopoietic Cell Transplant
  • Stem Cell Transplant Complications
  • EBV+ Sarcomas
  • Leiomyosarcoma
Interventions
  • BIOLOGICAL
No Results Yet
NCT04491942 | ACTIVE_NOT_RECRUITING | PHASE1
74 participants

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-08-25
Completion:
2027-06-30
Conditions
  • Advanced Bile Duct Carcinoma
  • Advanced Breast Carcinoma
  • Advanced Cervical Carcinoma
  • Advanced Endometrial Carcinoma
  • Advanced Esophageal Carcinoma
  • Advanced Gastric Carcinoma
  • Advanced Head and Neck Carcinoma
  • Advanced Lung Non-Small Cell Carcinoma
  • Advanced Lung Small Cell Carcinoma
  • Advanced Malignant Solid Neoplasm
  • Advanced Ovarian Carcinoma
  • Advanced Penile Carcinoma
  • Advanced Pleural Malignant Mesothelioma
  • Advanced Urothelial Carcinoma
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Stage III Cervical Cancer AJCC v8
  • Stage III Distal Bile Duct Cancer AJCC v8
  • Stage III Intrahepatic Bile Duct Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Penile Cancer AJCC v8
  • Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Stage IV Distal Bile Duct Cancer AJCC v8
  • Stage IV Intrahepatic Bile Duct Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8
  • Triple-Negative Breast Carcinoma
  • Unresectable Urothelial Carcinoma
Interventions
  • DRUG
No Results Yet
NCT04460937 | ACTIVE_NOT_RECRUITING | PHASE1
4 participants

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-04-09
Completion:
2024-03-29
Conditions
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
  • Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Distal Esophagus Adenocarcinoma
  • Gastric Cardia Adenocarcinoma
  • Metastatic Esophageal Adenocarcinoma
  • Metastatic Esophageal Squamous Cell Carcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Malignant Neoplasm in the Brain
  • Metastatic Malignant Neoplasm in the Leptomeninges
  • Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
  • Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
  • Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
  • Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Unresectable Esophageal Adenocarcinoma
  • Unresectable Esophageal Carcinoma
  • Unresectable Esophageal Squamous Cell Carcinoma
  • Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
  • DRUG
  • RADIATION
Results Available
NCT04458922 | ACTIVE_NOT_RECRUITING | PHASE2
27 participants

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-10-05
Completion:
2022-11-28
Conditions
  • Central Chondrosarcoma, Grade 2
  • Central Chondrosarcoma, Grade 3
  • Dedifferentiated Chondrosarcoma
  • Metastatic Clear Cell Sarcoma of Soft Tissue
  • Metastatic Primary Central Chondrosarcoma
  • Unresectable Primary Central Chondrosarcoma
Interventions
  • DRUG
  • PROCEDURE
Results Available
NCT04216316 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
12 participants

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-04-14
Completion:
2024-03-31
Conditions
  • Lung Non-Small Cell Squamous Carcinoma
  • Stage IV Lung Cancer AJCC v8
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
Results Available
NCT04175912 | ACTIVE_NOT_RECRUITING | PHASE2
40 participants

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-03-16
Completion:
2023-11-27
Conditions
  • Metastatic Cholangiocarcinoma
  • Metastatic Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage III Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Unresectable Cholangiocarcinoma
  • Unresectable Hepatocellular Carcinoma
  • Unresectable Intrahepatic Cholangiocarcinoma
Interventions
  • DRUG
Results Available
NCT04144972 | RECRUITING | NA
12 participants

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-10-24
Completion:
2029-10-24
Conditions
  • Spinal Cord Injuries
  • Nerve Injury
  • Pain, Postoperative
  • Post Herpetic Neuralgia
  • Complex Regional Pain Syndromes
  • Post-Stroke Pain
  • Post Radiation Brain Injury
  • Post Radiation Plexopathy
  • Nerve Root Avulsion
Interventions
  • DEVICE
No Results Yet
NCT04079712 | ACTIVE_NOT_RECRUITING | PHASE2
17 participants

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-08-06
Completion:
2025-01-10
Conditions
  • Metastatic Large Cell Neuroendocrine Carcinoma
  • Metastatic Neuroendocrine Carcinoma
  • Metastatic Neuroendocrine Neoplasm
  • Metastatic Small Cell Neuroendocrine Carcinoma
Interventions
  • BIOLOGICAL
  • DRUG
Results Available
NCT04071223 | ACTIVE_NOT_RECRUITING | PHASE2
134 participants

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-07-29
Completion:
2026-10-01
Conditions
  • Advanced Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Kidney Medullary Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
  • Papillary Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8
  • Unclassified Renal Cell Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • RADIATION
No Results Yet
NCT04052555 | ACTIVE_NOT_RECRUITING | PHASE1
42 participants

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-09-24
Completion:
2027-02-24
Conditions
  • Bilateral Breast Carcinoma
  • HER2-Negative Breast Carcinoma
  • Localized Breast Carcinoma
  • Recurrent Breast Carcinoma
  • Triple-Negative Breast Carcinoma
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • RADIATION
No Results Yet
NCT03914612 | ACTIVE_NOT_RECRUITING | PHASE3
813 participants

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-08-22
Completion:
2022-12-16
Conditions
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Recurrent Endometrial Adenocarcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Endometrial Clear Cell Adenocarcinoma
  • Recurrent Endometrial Dedifferentiated Carcinoma
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Endometrial Mixed Cell Adenocarcinoma
  • Recurrent Endometrial Serous Adenocarcinoma
  • Recurrent Endometrial Undifferentiated Carcinoma
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
Results Available
NCT03914300 | ACTIVE_NOT_RECRUITING | PHASE2
11 participants

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-02-10
Completion:
2024-10-17
Conditions
  • Differentiated Thyroid Gland Carcinoma
  • Follicular Variant Thyroid Gland Papillary Carcinoma
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Refractory Differentiated Thyroid Gland Carcinoma
  • Refractory Thyroid Gland Carcinoma
  • Tall Cell Variant Thyroid Gland Papillary Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Oncocytic Carcinoma
  • Thyroid Gland Papillary Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page